• Ferritin-Based Hybrid Vaccine Combines Influenza A and SARS-

  2026-05-19

  This study introduces a ferritin-based protein particle vaccine that co-displays the M2e antigen of influenza A and tandem S-protein epitopes of SARS-CoV-2 on a single nanoparticle. The platform leverages self-assembling ferritin to enhance immunogenicity and offers a promising approach for future combination vaccines against multiple pathogens.

• HBTU in Precision Peptide Bond Formation: Applied Workflows

  2026-05-19

  HBTU stands out as a racemization-resistant coupling reagent that empowers the synthesis of complex, enzyme-responsive peptides for cancer-selective therapeutics. This guide unpacks optimized workflows, troubleshooting, and experimental insights that leverage HBTU's unique properties for advanced peptide synthesis.

• Anlotinib Hydrochloride Suppresses Angiogenesis via Multi-Ta

  2026-05-18

  This article examines the 2018 study demonstrating that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly inhibits angiogenesis by simultaneously blocking VEGFR2, PDGFRβ, and FGFR1 signaling. The findings highlight anlotinib’s superior efficacy over established TKIs in endothelial migration and tube formation assays, offering valuable direction for cancer research and anti-angiogenic strategy development.

• BMS-777607 in Precision MET Pathway Inhibition and hiPSC Pla

  2026-05-18

  Explore how BMS-777607, a selective c-Met inhibitor, enables precise control of MET signaling for advanced cancer and stem cell research. This article uniquely bridges the mechanistic underpinnings with practical assay optimizations, offering actionable insights beyond standard protocol overviews.

• Cabozantinib (XL184, BMS-907351): Reliable Lab Solutions for

  2026-05-17

  This article addresses common experimental challenges in kinase inhibition, viability, and phosphoproteomics assays, showcasing how Cabozantinib (XL184, BMS-907351) (SKU A2977) from APExBIO delivers reproducible, literature-backed data in renal cell carcinoma and medullary thyroid cancer research. Scenario-driven Q&As guide scientists through workflow optimization, data interpretation, and vendor selection, with protocols and performance benchmarks rooted in recent systems-level evidence.

• SB743921: Applied Workflows for Kinesin Spindle Protein Inhi

  2026-05-16

  SB743921 stands out as a highly selective kinesin spindle protein inhibitor, enabling robust induction of mitotic arrest and apoptosis in a wide array of cancer models. This article translates the latest in vitro evaluation strategies into actionable protocols and troubleshooting tips, optimizing the use of SB743921 for translational cancer research.

• Chrysin Potentiates Sunitinib in RCC via PI3K/Akt/GPX4 Ferro

  2026-05-15

  This study demonstrates that chrysin, a natural flavonoid, enhances the anti-tumor efficacy of sunitinib in renal cell carcinoma (RCC) by promoting ferroptosis through inhibition of the PI3K/Akt/GPX4 pathway. The findings offer a mechanistic rationale for leveraging ferroptosis in overcoming sunitinib resistance, suggesting new combinatorial strategies for RCC research.

• Nonivamide (Capsaicin Analog): Reliable Pathways in Cell Ass

  2026-05-15

  This article provides scenario-driven insights into Nonivamide (Capsaicin Analog, SKU A3278) for optimizing cell viability, proliferation, and cytotoxicity experiments. Highlighting APExBIO's offering, it addresses common laboratory challenges, data-backed protocol parameters, and comparative vendor reliability. Researchers gain practical, evidence-based strategies for leveraging Nonivamide in cancer research and TRPV1 pathway studies.

• Mechanisms of PRC2 Recruitment and Inhibition on Chromatin

  2026-05-14

  This study redefines our understanding of PRC2 recruitment to chromatin by demonstrating that linker DNA, rather than histone modifications, is the dominant determinant of PRC2 binding, and that RNA inhibits PRC2 by competitive sequestration. These insights have broad implications for chromatin biology, gene regulation, and the design of biochemical assays involving chromatin complexes.

• Gastrin I (human): Powering Translational GI Physiology Mode

  2026-05-14

  Explore how human Gastrin I peptide unlocks advanced gastric acid secretion pathway research, bridging mechanistic insight with strategic protocols for translational teams. Emphasizing its pivotal role in hiPSC-derived organoid models and clinical relevance for GI disorder research, this thought-leadership article delivers actionable guidance, rigorous evidence integration, and a competitive roadmap for next-generation gastrointestinal physiology studies.

• Plant Nanovesicles Restore Sertoli Cell Cycle in Testicular

  2026-05-13

  This study demonstrates that exosome-like nanovesicles derived from Cistanche deserticola (CDELNs) are efficiently taken up by testicular Sertoli cells and ameliorate cyclophosphamide-induced testicular injury by alleviating cell cycle arrest. The findings provide new mechanistic insight into plant nanovesicle-mediated delivery of regulatory miRNAs, highlighting a potential therapeutic strategy for male reproductive toxicity.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Rese

  2026-05-13

  5-(N,N-dimethyl)-Amiloride hydrochloride offers precision inhibition of Na+/H+ exchangers, empowering researchers to dissect intracellular pH regulation and model ischemia-reperfusion or sepsis injury with confidence. Its selectivity and robust performance set a new benchmark for reproducible cardiovascular and endothelial workflows.

• GPNMB-Based Multimodal Models Predict Immunotherapy Response

  2026-05-12

  This study establishes a circulating GPNMB-centric multimodal model that integrates tumor-immune crosstalk to predict immunotherapy responses in esophageal squamous cell carcinoma (ESCC). By mechanistically linking the tumor microenvironment, soluble GPNMB, and CD8+ T cell exhaustion, the research provides a clinically scalable framework for precision patient stratification.

• Sisomicin: Reimagining Translational Antibiotic Research

  2026-05-12

  This thought-leadership article explores Sisomicin’s mechanistic power and translational potential as a broad-spectrum aminoglycoside antibiotic. Integrating recent advances in multidrug resistance research, protocol recommendations, and strategic insights, we guide innovators in infection biology to harness Sisomicin for cutting-edge antibacterial testing and model development. By synthesizing evidence from pivotal studies and workflow experience, this piece advances the dialogue beyond conventional product literature, positioning APExBIO’s Sisomicin at the frontier of translational research.

• Gemcitabine: Protocol Innovations for DNA Damage Response As

  2026-05-11

  Gemcitabine (4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one) empowers reproducible, high-sensitivity apoptosis and DNA damage response assays in advanced cancer research. This guide details stepwise protocol enhancements, troubleshooting strategies, and novel workflows inspired by emerging insights on chemotherapy resistance and metabolic crosstalk.

14763 records 5/985 page Previous Next 12345 下5页 Last page